Teacher Retirement System of Texas Increases Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Teacher Retirement System of Texas boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 137.5% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 64,200 shares of the company's stock after purchasing an additional 37,163 shares during the period. Teacher Retirement System of Texas owned approximately 0.08% of IDEXX Laboratories worth $26,961,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. Geode Capital Management LLC raised its position in shares of IDEXX Laboratories by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock worth $948,279,000 after acquiring an additional 37,734 shares during the period. Bamco Inc. NY grew its stake in IDEXX Laboratories by 4.3% during the 4th quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock valued at $829,163,000 after acquiring an additional 82,264 shares in the last quarter. Invesco Ltd. lifted its position in IDEXX Laboratories by 6.8% during the fourth quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock worth $479,999,000 after buying an additional 74,324 shares in the last quarter. Norges Bank acquired a new position in shares of IDEXX Laboratories during the 4th quarter valued at about $412,258,000. Finally, GAMMA Investing LLC increased its holdings in shares of IDEXX Laboratories by 59,810.7% during the 1st quarter. GAMMA Investing LLC now owns 918,431 shares of the company's stock worth $3,856,950,000 after buying an additional 916,898 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Analyst Ratings Changes

IDXX has been the topic of a number of research analyst reports. Stifel Nicolaus boosted their price target on shares of IDEXX Laboratories from $510.00 to $540.00 and gave the company a "hold" rating in a research note on Wednesday, July 2nd. Leerink Partners lifted their price objective on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 11th. Morgan Stanley raised their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Jefferies Financial Group started coverage on IDEXX Laboratories in a research note on Tuesday, July 1st. They set a "buy" rating and a $625.00 price target on the stock. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $558.11.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the transaction, the director directly owned 1,801 shares in the company, valued at approximately $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Price Performance

NASDAQ IDXX traded down $1.45 during trading hours on Monday, reaching $545.56. The company's stock had a trading volume of 445,216 shares, compared to its average volume of 646,147. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $549.49. The stock has a market cap of $43.87 billion, a PE ratio of 50.42, a PEG ratio of 3.99 and a beta of 1.54. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16. The company's 50-day moving average is $510.63 and its two-hundred day moving average is $455.17.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The firm had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. During the same period in the previous year, the firm posted $2.71 EPS. The company's quarterly revenue was up 3.6% compared to the same quarter last year. Analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.